Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Cancer Immunol Immunother. 2024 Mar 2;73(4):66. doi: 10.1007/s00262-024-03651-3.
Luminal and Basal are the primary intrinsic subtypes of muscle-invasive bladder cancer (MIBC). The presence of CD8 T cells infiltration holds significant immunological relevance, potentially influencing the efficacy of antitumor responses. This study aims to synergize the influence of molecular subtypes and CD8 T cells infiltration in MIBC.
This study included 889 patients with MIBC from Zhongshan Hospital, The Cancer Genome Atlas, IMvigor210 and NCT03179943 cohorts. We classified the patients into four distinct groups, based on the interplay of molecular subtypes and CD8 T cells and probed into the clinical implications of these subgroups in MIBC.
Among patients with Luminal-CD8T tumors, the confluence of elevated tumor mutational burden and PD-L1 expression correlated with a heightened potential for positive responses to immunotherapy. In contrast, patients featured by Luminal-CD8T displayed a proclivity for deriving clinical advantages from innovative targeted interventions. The Basal-CD8T subgroup exhibited the least favorable three-year overall survival outcome, whereas their Basal-CD8T counterparts exhibited a heightened responsiveness to chemotherapy.
We emphasized the significant role of immune-molecular subtypes in shaping therapeutic approaches for MIBC. This insight establishes a foundation to refine the process of selecting subtype-specific treatments, thereby advancing personalized interventions for patients.
腔面型和基底型是肌层浸润性膀胱癌(MIBC)的主要内在亚型。CD8 T 细胞浸润的存在具有重要的免疫学意义,可能影响抗肿瘤反应的疗效。本研究旨在综合分子亚型和 MIBC 中 CD8 T 细胞浸润的影响。
本研究纳入了来自中山医院、癌症基因组图谱、IMvigor210 和 NCT03179943 队列的 889 例 MIBC 患者。我们根据分子亚型和 CD8 T 细胞的相互作用将患者分为四个不同的组,并探讨了这些亚组在 MIBC 中的临床意义。
在腔面型-CD8T 肿瘤患者中,肿瘤突变负担和 PD-L1 表达升高的汇合与对免疫治疗产生积极反应的潜力增加相关。相比之下,表现为腔面型-CD8T 的患者更倾向于从创新的靶向干预中获得临床优势。基底型-CD8T 亚组的三年总生存率最差,而他们的基底型-CD8T 对应物对化疗的反应性更高。
我们强调了免疫-分子亚型在制定 MIBC 治疗方法中的重要作用。这一见解为细化选择特定亚型治疗的过程奠定了基础,从而推进了针对患者的个性化干预措施。